Medical technology company Glucotrack will host a virtual webinar to demonstrate its innovative Continuous Blood Glucose Monitor technology, presenting a potentially transformative approach to diabetes management. Current diabetes monitoring methods typically require patients to perform frequent finger-prick tests, which can be intrusive and cumbersome. Glucotrack's CBGM technology offers a more advanced alternative by providing real-time, continuous glucose tracking with significant technological advantages.
Unlike traditional continuous glucose monitoring devices that measure glucose levels in interstitial fluid with a time lag, Glucotrack's implantable device measures glucose directly in the bloodstream. This approach provides immediate, accurate readings without the delays associated with existing technologies. A key differentiator of Glucotrack's technology is its extended usability. While many current continuous glucose monitors require sensor replacement every ten to 90 days, Glucotrack's implant can function effectively for two to three years. This represents a substantial improvement in device longevity and patient convenience.
The company recently completed a preclinical study demonstrating the device's precision, achieving a Mean Absolute Relative Difference of 4.7% at 90 days, which is considered highly accurate in the medical technology field. The upcoming webinar will provide detailed insights into these research findings and the device's potential impact. The global diabetes landscape underscores the importance of innovative monitoring technologies. Projections indicate that diabetes will affect 643 million people worldwide by 2030, potentially increasing to 783 million by 2045. Glucotrack's technology could play a crucial role in managing this growing health challenge.
During the webinar, Glucotrack executives will explore how their CBGM technology works, share updates on clinical trials, and discuss the future of diabetes management. A live question-and-answer session will allow attendees to engage directly with the company's experts. The implications of this technology extend beyond individual patient convenience to potentially reducing healthcare system burdens associated with diabetes complications. By providing more accurate, continuous monitoring with fewer device replacements, this technology could improve treatment adherence and outcomes for millions living with diabetes globally.
